BTX 1801, page-25

great read scullero. thanks. BOT have 30 million cash so dont be surprised if they come out with some left field announcement. i hold 300k shares , f all so im not ramping. good luck holders.

This overuse of medication is occurring primarily because in many cases, they are being incorrectly prescribed. Studies show that antibiotic therapy is incorrect in30% to 50% of cases.

This alone can cause unnecessary antibacterial resistance andmany fearthis is precisely what will occur with regards to COVID-19.

This is whyBotanix Pharma(ASX:BOT) could be a wise investment given the early evidence surrounding their antimicrobial productBTX 1801.

Similarly to Zoono, studies revealed that Botanix's drug, BTX 1801, was capable of tackling a range of different bacteria, among both humans and animals. Additionally, thesynthetic CBDin Botanix's product kills bacteria within three hours and was shown to lessen the bacteria's ability to develop resistance to the antibiotics.

The cannabis-derived drug has so far proved effective against two superbugs, staphylococcus (staph infections) and methicillin-resistant staph Aureus (MRSA).

We've got our eyes onBotanix Pharmafor a number of reasons, but with regards to the current Coronavirus climate, positive results around BTX 1801 are likely to stimulate a lot of investor enthusiasm.

In order to progress BTX 1801 trials, the company received a $50,000 grant from the Federal Government, and Botanix will be beginning phase 2 of the trials in late Q1 of 2020.

Should the results ofBotanix'strial be positive, we may see cannabinoid formulas become a staple in addressing future bacterial diseases – and you can expect stock prices to rise at the same time.

Though Botanix isn't resting solely upon this formula either, as the company has several ongoing trials occurring, each targeting enormous addressable markets such asatopic dermatitis,acne, androsacea.

2020 will see the progression of many of these trials and should any one of these formulas show promise,Botanixmay be looking down the barrel of a billion-dollar formula.